Evgen Pharma PLC Rule 17 Disclosure (2489I)

TIDMEVG

RNS Number : 2489I

Evgen Pharma PLC

03 August 2023

Evgen Pharma plc

("Evgen" or "the Company" or "the Group")

Rule 17 Disclosure

Alderley Park, UK - 3 August 2023 : Evgen Pharma plc (AIM: EVG), a clinical stage drug development company developing sulforaphane-based medicines , notes that private UK-based cell and gene therapy company Ixaka Ltd has entered administration. Evgen's CEO, Huw Jones, is a non-executive director of Ixaka Ltd.

There are no further disclosures required pursuant to AIM Rule 17.

-Ends-

Enquiries:

 
 Evgen Pharma PLC 
  Dr Huw Jones, CEO 
  Dr H elen Kuhlman , CBO                       +44 1625 466591 
 FinnCap (Nominated Advisor and 
  Broker) 
  Geoff Nash / Teddy Whiley (Corporate 
  Finance) 
  Nigel Birks / Harriet Ward (ECM)             +44 20 7220 0500 
 Instinctif Partners                           +44 207 457 2020 
  Melanie Toyne-Sewell / Rozi Morris/      evgen@instinctif.com 
  Adam Loudon

Notes to Editors

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the highly biologically active compound sulforaphane and novel proprietary analogues based on sulforaphane.

The Company's lead asset, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive (ER+) metastatic breast cancer and recently a Phase 1b study of the Company's new enteric coated tablet formulation. The FDA has granted Orphan Drug status to SFX-01 in malignant glioma. SFX-01 will be investigated initially in this indication as an investigator sponsored study in the Netherlands.

The Company also has a wide number of collaborations with leading academic centres in the UK, Europe and the US as part of the continuing strategy to build the scientific data for the compound. Recently, Evgen completed an out-licensing transaction with Stalicla SA, a Swiss specialist company in neurodevelopmental disorders, commencing with autism spectrum disorder. The deal, if successful, will generate milestone payments of $160.5m and a double-digit royalty on sales.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is listed on AIM in London and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFLFVLTDIVIIV

(END) Dow Jones Newswires

August 03, 2023 07:38 ET (11:38 GMT)

Evgen Pharma (LSE:EVG)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025